Acute Malnutrition in Infancy (Disorder) Clinical Trial
Official title:
Evaluation of Two Optimizing and Simplifying Strategies on Acute Malnutrition Treatment in Children Aged 6 to 59 Months in Mirriah District, Zinder, Niger
NCT number | NCT04698070 |
Other study ID # | 35237 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 22, 2021 |
Est. completion date | June 24, 2022 |
Verified date | September 2022 |
Source | Alliance for International Medical Action |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute malnutrition (AM) is a continuum condition, arbitrarily divided into severe and moderate categories (SAM, MAM) which are managed separately, with programs overseen by different agencies with different products and supply chains. Such separation complicates delivery of care, contributes to poor program performance, and creates confusion among caregivers. Reduction in the mortality burden from AM will stem from improved simplicity, efficiency and cost-effectiveness of current protocols. Eligibility for SAM treatment in the current Niger protocol is complex. It is determined by 3 independent criteria: nutritional oedema, Mid-Upper Arm Circumference (MUAC) < 115 mm or weight-height Z score (WHZ) <-3. Also, the Ready to Use Therapeutic Food (RUTF) ration in Niger protocol (130-200 kcal/kg/d) is paradoxical. The amount of RUTF prescribed in the first weeks of treatment is often less than what given to child reaching recovery (MUAC > 125 and WHZ >-2), because weekly ration is determined by the child's weight. Rate of weight gain is highest in the first two weeks of treatment, then plateaus - suggesting no benefit of increased RUTF ration at the end of treatment. Progressive reduction is a more rational use of RUTF and this supplement is equally effective for SAM and MAM. This community-based non-inferiority trial will compare two strategies for the treatment of AM to the Niger protocol for SAM and MAM. The Optimizing treatment for acute MAlnutrition (OptiMA) strategy uses MUAC < 125 mm or nutritional oedema as admission criteria and optimizes RUTF by adapting doses to the degree of malnutrition. RUTF dose for MUAC < 115 mm or oedema is 170 kcal/kg/d and progressively reduces to 75 kcal/kg/d as MUAC increases. The Combined Protocol for Acute Malnutrition Study (ComPAS) uses the same eligibility criteria like OptiMA, but simplifies more the RUTF ration by providing 1000 kcal/d for children with oedema or MUAC < 115 mm and 500 kg/d for children with MUAC 115-124 mm. Children are considered recovered if they have 2 consecutive weekly MUAC measures ≥ 125 mm. Children will be individually randomized to treatment in one of the 3 study arms and will attend clinic visits weekly until nutritional recovery. After discharged, they will be monitored monthly via a nurse-conducted home visits until 6 months post-inclusion. The trial arms will be compared using a composite outcome indicator that includes vital status, anthropometric measures and relapse following the index AM episode. The hypothesis is that simplified strategies could substantially increase the number of children in care compared to current SAM programs without requiring additional RUTF or staffing while maintaining recovery rates in line with current programs.
Status | Completed |
Enrollment | 2304 |
Est. completion date | June 24, 2022 |
Est. primary completion date | March 22, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 59 Months |
Eligibility | Inclusion criteria: - Age 6 to 59 months old upon study inclusion - Meet one of the acute malnutrition criteria defined as follows: - MUAC < 125mm or - Weight for Length Z-score <-3 (WHO standard) or - Oedema grade + or ++; - Resident in health area where the study is conducted ; - Child's mother or guardian provides informed consent. Exclusion Criteria: - Children with medical condition requiring hospitalization or negative appetite test or oedema grade +++; - Children allergic to milk, peanuts and/or RUTFs ; - Children diagnosed with a chronic pathology such as sickle cell anemia, trisomy 21, congenital heart disease, neurological condition; - Children currently enrolled in another malnutrition programme. |
Country | Name | City | State |
---|---|---|---|
Niger | Diney | Mirriah | Zinder |
Niger | Droum | Mirriah | Zinder |
Niger | Gada | Mirriah | Zinder |
Niger | Gaffati | Mirriah | Zinder |
Lead Sponsor | Collaborator |
---|---|
Alliance for International Medical Action | Harvard School of Public Health (HSPH), University of Bordeaux, INSERM, Bordeaux Population Health |
Niger,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Assess the cost-effectiveness of OptiMA and ComPAS strategies compared to the national protocol of acute malnutrition treatment in Niger | The ICER (Incremental cost-effectiveness Ratio) will be estimated in each arm. | At 6 month | |
Other | Outpatient recovery rate | Recovery rate defined as follows: as follows: absence of bipedal oedema and MUAC > 125 mm during two consecutive weeks, a 4-week minimum duration of treatment as clinically well, i.e. axillary temperature <37.5°C will be estimated at the end of the outpatient follow up. | Throughout the 16-weeks outpatient follow up. | |
Other | Consumption of RUTF | The average number of RUTF sachets per child recovered and per child successfully treated | At the visit of recovery status occuring through the 6 month study completion | |
Other | Recovered children by RUTF quantity | The average number of successful and cured children for a given amount of RUTF. | At the visit of recovery status occuring through the 6 month study completion | |
Other | Relapse rate to a new episode of AM and to a new episode of SAM | Comparison of the proportion of children who relapse to a new episode of AM and to a new episode of SAM in SAM children at inclusion and in children with AM at inclusion between each arms and risk factors analysis. | Throughout the 6-month observation period | |
Other | Non-response rate | Comparison of the proportion of non response (children who did not recovered after 16 weeks under supplementation) in each arms and risk factors analysis. | At 16 weeks after inclusion | |
Other | Recovery rate of children without supplementation | Describe the recovery of children not receiving nutritional supplementation with RUTF when included in the standard protocol. | Throughout the 6-month observation period | |
Other | Recovery rate of WaST children | Comparison of the recovery rate of children with acute malnutrition associated with severe or moderate stunting in each arms. | Throughout the 6-month observation period | |
Other | Hospitalisation rate | Comparaison of the hospitalisation rate in children with AM at inclusion between both arms in each population | Throughout the 6-month observation period | |
Primary | Success rate | The primary outcome is a binary composite indicator. Children classified as 'success' fulfil all of the following criteria: alive, not acutely malnourished per the definition applied at inclusion and no additional episode of acute malnutrition (inclusion criteria) throughout the 6-month observation period. All other children are classified unsuccessful. | 6-month after randomisation | |
Secondary | Recovery rate in children with SAM WHO definition | The secondary priority outcome n°1 is the recovery rate in participants with severe acute malnutrition (WHO definition)defined as follows: absence of bipedal oedema and MUAC > 125 mm during two consecutive weeks, a 4-week minimum duration of treatment as clinically well, i.e. axillary temperature <37.5°C. This outcome will be measured throughout the 6-month observation period. All children reaching these criteria during outpatient treatment our during the home visit will be defined recovered. | Throughout the 6-month observation period | |
Secondary | Recovery rate in children with MUAC<115mm | The secondary priority outcome n°2 is the recovery rate in participants with MUAC<115mm defined as follows: absence of bipedal oedema and MUAC > 125 mm during two consecutive weeks, a 4-week minimum duration of treatment as clinically well, i.e. axillary temperature <37.5°C. This outcome will be measured throughout the 6-month observation period. All children reaching these criteria during outpatient treatment our during the home visit will be defined recovered. | Throughout the 6-month observation period |